AMAG Pharma (AMAG) – Press Releases
-
Landsdowne Labs Names Bryan Laulicht CEO
-
Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director
-
Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D., and Announces Resignation of Douglas K. Bratton from Board of Directors
-
AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration’s Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproat
-
Covis Group Completes Acquisition of AMAG Pharmaceuticals
-
MGIC Investment & Halozyme Therapeutics Set to Join S&P MidCap 400; First Bancorp, The Geo Group & Mednax to Join S&P SmallCap 600
-
Covis Group S.à r.l. Announces Commencement of Tender Offer for All Outstanding Shares of AMAG Pharmaceuticals, Inc.
-
AMAG Pharmaceuticals Requests Hearing to Maintain Makena® (Hydroxyprogesterone Caproate Injection) as a Treatment Option for Clinically Indicated Pregnant Patients
-
MERGER ALERT – ARA, MYOK, and AMAG: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
-
AMAG Pharmaceuticals Provides Update on FDA’s Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection)
-
MERGER ALERT - ARA, BLDR, and AMAG: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
-
MERGER ALERT – AMAG and STND: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
-
AMAG HOLDINGS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of AMAG and Encourages Investors to Contact the Firm
-
Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals
-
AMAG Pharmaceuticals to Participate in H.C. Wainwright 22nd Annual Global Investment Conference
-
AMAG Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Corporate Update
-
AMAG Pharmaceuticals to Host Second Quarter FY 2020 Financial Results Conference Call and Webcast on Thursday, August 6, 2020
-
AMAG Pharmaceuticals Completes Divestment of Women’s Health Assets
-
AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand
-
AMAG Announces Presentation of Ciraparantag Data at the International Society on Thrombosis and Haemostasis
-
AMAG Pharmaceuticals Announces Leadership Changes
-
AMAG Pharmaceuticals to Participate in Jefferies Virtual Global Healthcare Conference
-
AMAG Pharmaceuticals Completes Sale of its Rights to Intrarosa® to Millicent Pharma for up to $125 Million
-
AMAG Pharmaceuticals Announces First Quarter 2020 Financial Results and Provides Corporate Update
-
AMAG Pharmaceuticals Appoints Scott Myers as President and Chief Executive Officer
-
AMAG Pharmaceuticals to Host First Quarter 2020 Financial Results Conference Call and Webcast on Monday, May 11, 2020
-
AMAG Pharmaceuticals Provides COVID-19 Company Update
-
AMAG Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
-
AMAG Pharmaceuticals Announces Changes to Medical Development Organization
-
AMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Wednesday, March 4, 2020 at 8:00 a.m. ET
-
AMAG Pharmaceuticals to Participate in Upcoming Investor Conferences
-
AMAG Pharmaceuticals Announces Leadership Transition, Results of Strategic Review to Unlock Shareholder Value and Financial Update
-
AMAG Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference
-
AMAG Pharmaceuticals Awards Four Grants to Support Preterm Birth and Preeclampsia Research
-
AMAG Pharmaceuticals to Present at Upcoming Investor Conferences
-
AMAG Pharmaceuticals Announces Third Quarter 2019 Financial Results and Provides Corporate Update
-
AMAG Reports on FDA Advisory Committee Meeting for Makena® (Hydroxyprogesterone Caproate Injection)
-
AMAG Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee Meeting to Discuss the Results of the Makena PROLONG Trial
-
AMAG Pharmaceuticals Announces the Publication of the PROLONG Trial Evaluating 17-OHPC in the American Journal of Perinatology
-
AMAG Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on Friday, November 1, 2019 at 8:00 a.m. ET
-
AMAG Pharmaceuticals Announces the Publication of the Phase 3 Vyleesi™ (Bremelanotide Injection) Data in Obstetrics & Gynecology
-
AMAG Pharmaceuticals Announces Settlement Agreement with Caligan Partners LP
-
Caligan Partners Issues Letter to AMAG Shareholders
-
AMAG Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
-
AMAG Files Definitive Consent Revocation Statement and Sends Letter to Shareholders
-
Caligan Partners Launches Consent Solicitation Process and Sends Letter to AMAG Shareholders
-
AMAG Sends Letter to Shareholders
-
AMAG Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
-
AMAG Urges Stockholders to Take No Action on Caligan Partners’ Consent Solicitation Materials
-
AMAG Pharmaceuticals Announces Commercial Availability of Vyleesi™ (Bremelanotide Injection)
Back to AMAG Stock Lookup
